KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.

被引：0
|
作者：
Wakelee, Heather A.
Liberman, Moishe
Kato, Terufumi
Tsuboi, Masahiro
Lee, Se-Hoon
He, Jie
Gao, Shugeng
Chen, Ke-Neng
Dooms, Christophe Alfons
Majem, Margarita
Eigendorff, Ekkehard
Martinengo, Gaston Lucas
Bylicki, Olivier
Rodriguez-Abreu, Delvys
Chaft, Jamie E.
Novello, Silvia
Yang, Jing
Keller, Steven M.
Samkari, Ayman
Spicer, Jonathan
机构：
[1] Stanford Univ, Stanford Canc Inst, Div Oncol, Dept Med, Stanford, CA USA
[2] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[3] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[5] Sungkyunkwan Univ, Div Hematol Oncol, Dept Internal Med, Samsung Med Ctr,Sch Med, Seoul, South Korea
[6] Chinese Acad Med Sci & Peking, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
[7] Chinese Acad Med Sci & Pek, Dept Thorac Surg, Natl Clin Res Ctr Canc, Canc Hosp,Natl Canc Ctr, Beijing, Peoples R China
[8] Beijing Canc Hosp, Beijing, Peoples R China
[9] Univ Hosp Leuven, Leuven, Belgium
[10] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[11] Zentralklin Bad Berka GmbH, Bad Berka, Germany
[12] Sanatorio Parque, Santa Fe, Argentina
[13] HIA SAINTE ANNE, Toulon, France
[14] Complejo Hosp Univ Insular Materno Infantil, Las Palmas Gran Canaria, Spain
[15] Mem Sloan Kettering Canc Ctr, New York, NY USA
[16] Univ Turin, AOU San Luigi Orbassano, Turin, Italy
[17] Merck & Co Inc, Rahway, NJ USA
[18] Merck & Co Inc, Kenilworth, NJ USA
[19] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA100
引用
收藏
页数：1
相关论文
共 50 条
  • [1] KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC
    Wakelee, Heather A.
    Liberman, Moishe
    Kato, Terufumi
    Tsuboi, Masahiro
    Lee, Se-Hoon
    He, Jie
    Gao, Shugeng
    Chen, Ke-Neng
    Dooms, Christophe Alfons
    Majem, Margarita
    Eigendorff, Ekkehard
    Martinengo, Gaston Lucas
    Bylicki, Olivier
    Rodriguez-Abreu, Delvys
    Chaft, Jamie E.
    Novello, Silvia
    Yang, Jing
    Keller, Steven M.
    Samkari, Ayman
    Spicer, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA100 - LBA100
  • [2] Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671.
    Fernando, Hiran C.
    Yang, Jing
    Ferraro, Geri L.
    Keller, Steven M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
    Spicer, Jonathan D.
    Garassino, Marina C.
    Wakelee, Heather
    Liberman, Moishe
    Kato, Terufumi
    Tsuboi, Masahiro
    Lee, Se-Hoon
    Chen, Ke-Neng
    Dooms, Christophe
    Majem, Margarita
    Eigendorff, Ekkehard
    Martinengo, Gaston L.
    Bylicki, Olivier
    Rodriguez-Abreu, Delvys
    Chaft, Jamie E.
    Novello, Silvia
    Yang, Jing
    Arunachalam, Ashwini
    Keller, Steven M.
    Samkari, Ayman
    Gao, Shugeng
    LANCET, 2024, 404 (10459): : 1240 - 1252
  • [4] KEYNOTE-604: Phase 3 Randomized, Double-Blind Trial of Pembrolizumab/Placebo plus Etoposide/Platinum for Extensive Stage-SCLC
    Rudin, C.
    Shen, L.
    Pietanza, M. C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2400 - S2400
  • [5] Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study
    Schmid, P.
    Cortes, J.
    Dent, R. A.
    Pusztai, L.
    McArthur, H. L.
    Kummel, S.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Foukakis, T.
    Reynier, M. A. Mouret
    Ferreira, M. I. R.
    Im, S. A.
    Cardoso, F.
    Ding, Y.
    Pan, W.
    Tryfonidis, K. E.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1257 - S1257
  • [6] Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
    Kuemmel, S.
    Schmid, P.
    Harbeck, N.
    Takahashi, M.
    Untch, M.
    Boileau, J. -F.
    Cortes, J.
    McArthur, H.
    Dent, R.
    O'Shaughnessy, J.
    Pusztai, L.
    Foukakis, T.
    Park, Y. H.
    Hui, R.
    Cardoso, F.
    Denkert, C.
    Zhu, Y.
    Pan, W.
    Karantza, V.
    Fasching, P.
    BREAST, 2023, 68 : S63 - S64
  • [7] Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early TNBC: Surgical Outcomes from the Phase 3 KEYNOTE-522 Study
    Kuemmel, Sherko
    Schmid, Peter
    Harbeck, Nadia
    Takahashi, Masato
    Untch, Michael
    Boileau, Jean-Francois
    Cortes, Javier
    McArthur, Heather
    Dent, Rebecca
    O'Shaughnessy, Joyce
    Pusztai, Lajos
    Foukakis, Theodoros
    Park, Yeon Hee
    Hui, Rina
    Cardoso, Fatima
    Denkert, Carsten
    Zhu, Yalin
    Pan, Wilbur
    Karantza, Vassiliki
    Fasching, Peter A.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 2) : S295 - S296
  • [8] KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC
    Gandhi, Leena
    Rodgriguez-Abreu, Delvys
    Gadgeel, Shirish
    Esteban, Emilio
    Felip, Enriqueta
    De Angelis, Flavia
    Domine, Manuel
    Clingan, Philip
    Hochmair, Maximilian J.
    Powell, Steven
    Cheng, Susanna Yee-Shan
    Bischoff, Helge G.
    Peled, Nir
    Grossi, Francesco
    Jennens, Ross R.
    Reck, Martin
    Hui, Rina
    Garon, Edward B.
    Boyer, Michael
    Rubio-Viqueira, Belen
    Novello, Silvia
    Kurata, Takayasu
    Gray, Jhanelle E.
    Vida, John J.
    Wei, Ziwen
    Yang, Jing
    Raftopoulos, Harry
    Pietanza, M. Catherine
    Garassino, Marina C.
    CANCER RESEARCH, 2018, 78 (13)
  • [9] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
    Colombo, N.
    Dubot, C.
    Lorusso, D.
    Caceres, V.
    Hasegawa, K.
    Shapira-Frommer, R.
    Tewari, K. S.
    Salman, P.
    Hoyos, E.
    Yanez, E.
    Gumus, M.
    De Mendoza, M. Olivera Hurtado
    Samouelian, V.
    Castonguay, V.
    Arkhipov, A.
    Toker, S.
    Li, K.
    Keefe, S. M.
    Monk, B. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1307 - S1308
  • [10] KEYNOTE-522: Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early-stage Triple Negative Breast Cancer
    McArthur, Heather
    Cortes, Javier
    Dent, Rebecca
    Pusztai, Lajos
    Kuemmel, Sherko
    Bergh, Jonas
    Denkert, Carsten
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Untch, Michael
    Fasching, Peter A.
    Cardoso, Fatima
    Andersen, Jay
    Patt, Debra
    Danso, Michael
    Ferreira, Marta
    Mouret-Reynier, Marie-Ange
    Im, Seock-Ah
    Ahn, Jin-Hee
    Gion, Maria
    Baron-Hay, Sally
    Boileau, Jean-Francois
    Zhu, Yalin
    Pan, Wilbur
    Tryfonidis, Konstantinos
    Karantza, Vassiliki
    O'Shaughnessy, Joyce
    Schmid, Peter
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 338 - 338
12345